Wockhardt profit dives as faces U.S., UK regulator demands

By Aradhana Aravindan and Sumeet Chatterjee MUMBAI (Reuters) – Wockhardt Ltd faces a year or more to get U.S. and British regulators to end curbs on its shipments of medicines to the two countries, the Indian drugmaker said on Friday after posting its smallest profit in six quarters. Indian firms, which make nearly 40 percent of generic and over-the-counter drugs for the U.S. market, face more regulatory woes, including a record fine for Ranbaxy Laboratories, amid increased scrutiny by overseas regulators. …